OBJECTIVE: To study a new and practical method to prevent the superficial bladder tumor recurrence after transurethral resection of bladder tumor (TUR-Bt). METHODS: We had chosen 68 patients with superficial bladder tumor randomly. After TUR-Bt, we inserted special stainless steel injection needle through the operation hole, and then injected anti-tumor drugs (pirarubicin) submucously; in the control group, 74 patients were given traditional perfusion therapy for carcinoma in bladder with the same anti-tumor drug (pirarubicin) after TUR-Bt. The effects were evaluated according to recurrence ratio. RESULTS: The recurrence rate of injection group was 11.8% (8/68), and that of the control group was 29.7% (22/74). There is a very significant difference between the two groups (chi(2) = 0.013, P < 0.01). The overall median recurrence interval period of injection group was obviously longer than that of the control group, but there was no significant difference about single and multiple occurrences between the two groups (chi(2) = 0.719, P > 0.05). CONCLUSIONS: The injection method used to prevent tumor recurrence after TUR-Bt has the following virtues: simple and safe, less side effect, more economical. We demonstrated that submucosal injection is a practical method to prevent tumor recurrence and is worth popularizing.
RCT Entities:
OBJECTIVE: To study a new and practical method to prevent the superficial bladder tumor recurrence after transurethral resection of bladder tumor (TUR-Bt). METHODS: We had chosen 68 patients with superficial bladder tumor randomly. After TUR-Bt, we inserted special stainless steel injection needle through the operation hole, and then injected anti-tumor drugs (pirarubicin) submucously; in the control group, 74 patients were given traditional perfusion therapy for carcinoma in bladder with the same anti-tumor drug (pirarubicin) after TUR-Bt. The effects were evaluated according to recurrence ratio. RESULTS: The recurrence rate of injection group was 11.8% (8/68), and that of the control group was 29.7% (22/74). There is a very significant difference between the two groups (chi(2) = 0.013, P < 0.01). The overall median recurrence interval period of injection group was obviously longer than that of the control group, but there was no significant difference about single and multiple occurrences between the two groups (chi(2) = 0.719, P > 0.05). CONCLUSIONS: The injection method used to prevent tumor recurrence after TUR-Bt has the following virtues: simple and safe, less side effect, more economical. We demonstrated that submucosal injection is a practical method to prevent tumor recurrence and is worth popularizing.